Farmson unveils ₹300 Crore Acetic Anhydride unit in Vadodara

Farmson Basic Drugs unveiled its state-of-the-art  Unit-VI manufacturing facility in Nandesari, Vadodara, Gujarat. This modern  expansion signifies a key milestone in transforming Farmson into a fully  integrated producer of Paracetamol. 

The ₹300 Crore investment establishes Unit-VI as a crucial part of Farmson’s  vertical integration strategy. The inauguration on November 5, 2025, demonstrated the strength of  Farmson’s long-standing partnership with Haleon. Key Haleon executives  present included Richard Crane (Chief Procurement Officer), Raman  Singh (Director of API/Excipients & OTC Innovation), and Harpreet Basra  (Global Category Lead – API). 

This initiative fundamentally changes Farmson’s market stance. By fully  controlling the supply chain from raw materials to the finished API, Farmson  improves efficiency and oversight, setting a new standard in the industry.  Significantly, the plant will also create at least 150 new jobs in Vadodara and  nearby areas; fostering local economic growth. 

During the inauguration, Vinit Menon, CEO of Farmson Basic Drugs Private  Limited, highlighted the facility’s national significance. He stated, “Unit-VI is  more than just a corporate milestone; it represents a major investment in 

India’s pharmaceutical self-reliance. By manufacturing critical raw  materials like Acetic Anhydride in-house, we are reducing the risks  associated with the global supply of essential medicines such as  Paracetamol. This unwavering focus on high-quality domestic production  directly supports Prime Minister Modi’s vision of ‘Make in India’ the  undisputed ‘Pharmacy of the World.’ We are building a strong, reliable  domestic capacity to confidently serve the global healthcare community.” 

The successful launch of Unit-VI demonstrates the strong, shared commitment  to integrity and innovation that characterizes the long-standing partnership  between Farmson and Haleon.